Why Immunovant, Inc.’s (IMVT) Stock Is Up 5.05%
As of Tuesday, July 07, Immunovant, Inc.’s IMVT share price has surged by 5.05%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Commentary & Analysis
Why Immunovant, Inc.’s (IMVT) Stock Is Up 7.89%
As of Monday, June 22, Immunovant, Inc.’s IMVT share price has surged by 7.89%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Immunovant, Inc.’s (IMVT) Stock Is Down 5.74%
As of Tuesday, June 02, Immunovant, Inc.’s IMVT share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Michael Rose
Why Immunovant, Inc.’s (IMVT) Stock Is Down 6.47%
As of Thursday, May 21, Immunovant, Inc.’s IMVT share price has dipped by 6.47%, which has investors questioning if this is right time to buy.Michael Rose
Why Immunovant, Inc.’s (IMVT) Stock Is Up 22.50%
As of Wednesday, May 20, Immunovant, Inc.’s IMVT share price has surged by 22.50%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | IMVT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7,971.3 | $252.6 | 74% |
|
| Shares Out (Mil) | 203.7 | 52.3 | 77% |
|
| Institutional Ownership | 98.2% | 92.1% | 78% |
|
| Float (Mil) | 79.8 | 40.2 | 57% |
|
| Beta | 0.77 | 0.95 | 45% |
|
| Avg Daily Volume (000s) | 905 | 455 | 69% |
|
| Price Change (52-week) |
132.4% | 52.9% | 95% |
|
| Growth | IMVT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (36.3%) | (9.9%) | 11% |
|
| EPS (5yr) | (17.8%) | 16.0% | 15 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (21.3%) | (15.6%) | 31% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 5 | 4 | |
| Current EPS | ($0.479) | ($2.525) | ($2.129) | |
| Month Ago EPS | ($0.479) | ($2.444) | ($2.436) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.920) | ($2.584) | ($2.382) | |
| Year/Year Chg | (34.0%) | (8.9%) | (94.4%) | |
| Financials | IMVT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($506) | ($43) | 3% |
|
| EPS (TTM) | ($2.772) | ($1.600) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($407) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $7,043 | $180 | 68% |
|
| Valuation | IMVT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.24 | 2.56 | 89% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | IMVT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (58.3%) | (49.8%) | 10% |
|
| ROE | (64.8%) | (55.5%) | 13% |
|
| Liabilities to Assets | 10.9% | 30.3% | 6% |
|
| F-Score | 1 | 3 | 1% |
|
Immunovant, Inc. did not pass any screens on 7/31/2026.
